Cabozantinib Approved as First-line Therapy for Advanced Renal Cell Carcinoma

Share this content:
The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.
The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.

The US Food and Drug Administration (FDA) granted regular approval to cabozantinib as a first-line therapy for patients with advanced renal cell carcinoma (RCC).1

The drug, which inhibits multiple tyrosine kinases, was previously approved for pretreated advanced RCC.

The FDA based its approval on data from the open-label, phase 2 CABOSUN study (ClinicalTrials.gov Identifier: NCT01835158), for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib 60 mg daily or sunitinib 50 mg daily for 4 weeks on, then 2 weeks off. Patients had been diagnosed with intermediate- or poor-risk RCC.

Median progression-free survival was 8.6 months (95% CI, 6.8-14.0) vs 5.3 months (95% CI, 3.0-8.2) for patients in the cabozantinib arm vs the sunitinib arm, respectively (hazard ratio [HR], 0.48; 95% CI, 0.31-0.74; P = .0008).2

Patients in the cabozantinib arm had an overall response rate (ORR) of 33% (95% CI, 23%-44%) compared with 12% (95% CI, 5.4%-21%) in the sunitinib arm.

The most frequently reported grade 3 to 4 adverse events included hypertension, hypotension, syncope, diarrhea hypophosphatemia, hyponatremia, fatigue, stomatitis, pain, and decreased appetite.

References

  1. FDA grants regular approval to Cabometyx for first-line treatment of advanced renal cell carcinoma [news release]. Silver Spring, MD: US Food and Drug Administration; December 19, 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589842.htm. Accessed December 20, 2017.
  2. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib vs sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591-7. doi: 10.1200/JCO.2016.70.7398

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs